New heart failure inotrope could be 'Holy Grail' Family Practice News Digital Network AMSTERDAM – The novel intravenous inotropic agent omecamtiv mecarbil achieved greater reduction in dyspnea scores and less likelihood of worsening heart failure at the highest dose studied, compared with placebo, in patients with acute ... Amgen/Cytokinetics Drug Misses Primary Endpoint |
